Claassen I, Meylis J, van der Ley P, Peeters C, Brons H, Robert J, Borsboom D, van der Ark A, van Straaten I, Roholl P, Kuipers B, Poolman J
Laboratory for the Control of Biological Products, National Institute for Public Health and Environmental Protection, Bilthoven, The Netherlands.
Vaccine. 1996 Jul;14(10):1001-8. doi: 10.1016/0264-410x(96)00020-5.
An experimental serogroup B meningococcal vaccine was prepared from two genetically engineered strains; each expressing three different class 1 outer membrane proteins (OMPs) (PorA). The two strains expressed the subtypes P1.7,16;P1.5,2;P1.19,15 and P1.5c,10;P1.12,13;P1.7h,4, respectively. Outer membrane vesicles (OMV) were prepared from these strains by deoxycholate extraction, mixed with aluminiumphosphate as adjuvant and formulated to final vaccines. The class 1 OMPs represent ca 90% of the protein in the vaccine. The vaccine was found safe for human use and induced a bactericidal immune response in mice against five of the six wild type strains, which served as donors for the various por A genes.
一种实验性B群脑膜炎球菌疫苗由两种基因工程菌株制备而成;每种菌株表达三种不同的1类外膜蛋白(OMPs)(PorA)。这两种菌株分别表达P1.7,16;P1.5,2;P1.19,15和P1.5c,10;P1.12,13;P1.7h,4亚型。通过脱氧胆酸盐提取从这些菌株中制备外膜囊泡(OMV),与磷酸铝作为佐剂混合并配制成最终疫苗。1类OMPs约占疫苗中蛋白质的90%。该疫苗被发现对人类使用安全,并在小鼠中诱导了针对六种野生型菌株中五种的杀菌免疫反应,这些野生型菌株是各种por A基因的供体。